anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A discrete solid unit dosage of a pharmaceutical composition for oral administration, comprising celecoxib in a form of articles in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients, and having relative bioavailability not less than about 50%, preferably not less than about 70%, by comparison with an orally delivered solution containing an equivalent amount of celecoxib. 2. A discrete solid unit dosage of a pharmaceutical composition for oral administration, comprising celecoxib in a form of articles in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients, and having a distribution of celecoxib particle sizes such that D90 if the particles are less than 200 mum, preferably less than 100 mum, more preferably less than 40 mum, and most preferably less than 25 mum, in the longest dimension of said particles. 3. A discrete solid unit dosage for oral administration according to claim 2, having relative bioavailability not less than about 50%, preferably not less than about 70%, by comparison with an orally delivered solution containing an equivalent amount of celecoxib. 4. A discrete solid unit dosage for oral administration according to any one of claims 1 to 3 selected from the group comprising tablets, pills, hard or soft capsules, lozenges, sachets or pastilles. 5. A discrete solid unit dosage for oral administration according to claim 4, prepared in the form of unit dosage capsules or tablets, wherein said excipients are selected from the group consisting of pharmaceutically acceptable diluents, disintegrants, binding agents, wetting agents and lubricants. 6. A discrete solid unit dosage for oral administration according to claim 5, comprising (a) one or more pharmaceutically acceptable diluents in a total amount of about 10% to about 85% by weight of the composition; (b) one or more pharmaceutically acceptable disintegrants in a total amount of about 0.2% to about 10% by weight of the composition; and (c) one or more pharmaceutically acceptable binding agents in an amount of about 0.5% to about 10% by weight of the composition; (d) one or more pharmaceutically acceptable wetting agents in a total amount of about 0.4% to about 10% by weight of the composition; and (e) one or more pharmaceutically acceptable lubricants in a total amount of about 0.2% to about 8% by weight of the composition. 7. A discrete solid unit dosage for oral administration according to claim 6 wherein (a) said diluents comprise lactose; (b) said disintegrants comprise croscarmellose sodium; (c) said binding agents comprise polyvinylpyrrolidone; (d) said wetting agents comprise sodium lauryl sulfate; and (e) said lubricants comprise magnesium stearate. 8. A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising orally administering to the subject a dosage unit according to any one of claims 1 to 7 once or twice a day. 9. A method according to claim 8 wherein the condition or disorder is rheumatoid arthritis, osteoarthritis or pain.
On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
A diagnostic method and apparatus facilitating a test for diagnosing attention deficit hyperactivity disorder (ADD/ADHD) in a person is disclosed, which in many embodiments includes a visual problem solving test involving distinctive feature analysis. It facilitates making objective observations of multiple components of attention and executive functioning. This test in some embodiments consists of a 24 individual test items with plates of geometric faces. The test requires the subjects to select two identical faces out a field of faces that progressively increase in number and complexity. The geometric faces could instead be graphic faces, stick figures, geometric shapes or other visual stimuli in other embodiments. Correct/incorrect scores and response times are compared to normative data and coupled with structured behavioral observations to provide objective evidence of the subject's attentional and executive functioning status.
Irbesartan

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including irbesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. The antihypertensive effect of ARBs may be attenuated by NSAIDs. Therefore, monitor renal function and blood pressure periodically in patients receiving irbesartan and NSAID therapy.

Hydrochlorothiazide 

Administration of a non-steroidal anti-inflammatory agent, including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. Therefore, when Irbesartan and Hydrochlorothiazide Tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
After approval from the IRB of King Edward Medical University, and taking informed consent from parents of the participants, total of 120 neonates fulfilling inclusion and exclusion criteria will be enrolled and randomly allocated in two groups; group A and group B. All demographic details of participants in both groups be collected. In group A, neonates will be given bCPAP for respiratory support while neonates in group B, will be given nasal oxygen as control group. Neonates in both groups will be followed for 48 hours. The effectiveness will be determined by the reduction in Silverman Anderson Retraction Score (SARS) up to or less than 3, at the end of 48 hours. Data will be collected and analysed.
While inflammation is beneficial for insulin secretion during homeostasis, its transformation adversely affects β cells and contributes to diabetes. However, the regulation of islet inflammation for maintaining glucose homeostasis remains largely unknown. Here, we identified pericytes as pivotal regulators of islet immune and β cell function in health. Islets and pancreatic pericytes express various cytokines in healthy humans and mice. To interfere with the pericytic inflammatory response, we selectively inhibited the TLR/MyD88 pathway in these cells in transgenic mice. The loss of MyD88 impaired pericytic cytokine production. Furthermore, MyD88-deficient mice exhibited skewed islet inflammation with fewer cells, an impaired macrophage phenotype, and reduced IL-1β production. This aberrant pericyte-orchestrated islet inflammation was associated with β cell dedifferentiation and impaired glucose response. Additionally, we found that Cxcl1, a pericytic MyD88-dependent cytokine, promoted immune IL-1β production. Treatment with either Cxcl1 or IL-1β restored the mature β cell phenotype and glucose response in transgenic mice, suggesting a potential mechanism through which pericytes and immune cells regulate glucose homeostasis. Our study revealed pericyte-orchestrated islet inflammation as a crucial element in glucose regulation, implicating this process as a potential therapeutic target for diabetes.
The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
PROBLEM TO BE SOLVED: To obtain a strong and safe calcium antagonist useful as a therapeutic medicine for ischemic heart diseases, e.g. cardiotonic agents or cardiac infarction by including an uridine alkylphosphate compound as an active ingredient. SOLUTION: This calcium antagonist comprises an uridine 5'-alkyl phosphate compound of the formula (R is an alkyl), e.g. uridine 5'-hexadecyl phosphate an active ingredient. The compound of the formula is obtained by dissolving, e.g. uridine 5'-monophosphate and an alkyl alcohol in tert-butyl alcohol and reacting uridine 5'-monophosphate in the presence of dicyclohexylcarbodiimide usually at 60-100 deg.C for 2-20 hr. The compound of the formula can be administered by oral, parenteral, transrectal or percutaneous administration and the compound is preferably administered to each of adult patients at a daily total dose of 1-2,000 mg in the case of oral administration and 0.1-400 mg in the case of parenteral administration.
As a new type of pollutant, microplastics (MPs) commonly exist in today's ecosystems, causing damage to the ecological environment and the health of biological organisms, including human beings. MPs can function as carriers of heavy metals (HMs) to aggravate the enrichment of HMs in important organs of organisms, posing a great threat to health. Ferroptosis, a novel process for the regulation of nonapoptotic cell death, has been shown to be closely related to the occurrence and processes of MPs and HMs in diseases. In recent years, some HMs, such as cadmium (Cd), iron (Fe), arsenic (As) and copper (Cu), have been proven to induce ferroptosis. MPs can function as carriers of HMs to aggravate damage to the body. This damage involves oxidative stress, mitochondrial dysfunction, lipid peroxidation (LPO), inflammation, endoplasmic reticulum stress (ERS) and so on. Therefore, ferroptosis has great potential as a therapeutic target for diseases induced by MPs combined with HMs. This paper systematically reviews the potential effects and regulatory mechanisms of MPs and HMs in the process of ferroptosis, focusing on the mitochondrial damage, Fe accumulation, LPO, ERS and inflammation caused by MPs and HMs that affect the regulatory mechanism of ferroptosis, providing new insights for research on regulating drugs and for the development of ferroptosis-targeting therapy for Alzheimer's disease, Parkinson's disease, cancer and cardiovascular disease.
The invention discloses a composition for adjuvant treatment on occlusion of the central retinal artery and a preparing method of the composition. The composition is prepared from traditional Chinese medicine ingredients and Western medicine ingredients. The traditional Chinese medicine ingredients include whole grass of cayratia japonica (thunb.) gagnep.var.pubifolia merr. et chun, argy wormwood fruits, whole grass of triaenophora rupestris (Hemsl.) solereder, fruits or roots or involucre of quercus fabri hance, common selfheal fruit-spikes, whole grass of oxalis acetosella L., rosa multiflora flowers, whole grass of lamium amplexicaule, whole grass of walking spleenwort with roots, whole grass or roots of amaranthus spinosus, roots of tetrapanax papyrifer, edgeworthia chrysantha flower extract and common selfheal fruit-spike extract. The Western medicine ingredients include sodium citrate, isosorbide mononitrate, indapamide and the vitamin B2. According to the traditional Chinese and Western medicine combined theory, medicine is applied according to indications and scientifically matched, and the composition has the effects of promoting blood circulation to remove blood stasis, removing the liver-fire to improve eyesight, dredging collaterals and relieving swelling, diminishing inflammation and reducing pressure, regulating organism metabolism, promoting recovery of the retina and resisting infection. The composition for adjuvant treatment on occlusion of the central retinal artery is simple in preparing process, remarkable in treatment effect, mild in medicine effect and good in medical value.
A remedy for the treatment of tumours is obtained by the extraction of whole shell fish, crustaceans or fishes (e.g. herring, haddock and cod fish) with water or with a neutral organic solvent miscible with water in the presence of water, in particular with aqueous alcohol or acetone, the extract being freed from protein and after purification if necessary concentrated by removal of solvent.  Mussels are a convenient raw material; oysters, crayfish and lobsters and creatures of the orders of echinoderms and coelenterates are also available. The crude extract may be purified by shaking with ether and from the watery residue the active substance may be precipitated by the addition of anhydrous alcohol or acetone.  The substance may be further purified by treatment of an aqueous solution with an oxidizing agent, e.g. potassium permanganate or hydrogen peroxide. The material may also be purified by adsorption, e.g. in active charcoal.
An apparatus for delivering a bolus of a medical agent to a patient. The apparatus comprises a pump mechanism, a data input device, and a processor in data communication with the keypad and arranged to control the pump mechanism. The processor is programmed to receive data specifying a bolus amount through the data port, receive data regarding duration through the data port, receive a percentage through the data port, the percentage defining a portion of the bolus amount to deliver immediately upon executing a deliver command and a remainder of the bolus amount to deliver over the duration upon executing a deliver command, and execute the deliver command thereby controlling the pump mechanism to deliver the bolus. Also a method of temporarily adjusting the delivery rate of an infusion pump. The infusion pump is programmed to deliver a basal rate. The method comprises prompting a user to select whether to enter the temporary rate as a percent of the current delivery rate or as a new delivery rate; entering into the pump a period of time having a beginning and an end; entering into the pump a temporary basal rate; and delivering the therapeutic agent at a delivery rate substantially equal to the temporary basal rate during the period of time.
This is a non-significant risk multicenter, longitudinal specimen collection study. At the Baseline Visit, whole blood will be collected to be paired with either a previously collected tumor biopsy tissue sample or a prospectively collected tumor tissue sample. Whole blood samples will also be collected longitudinally at Interim visits for up to 5 years. Interim visits will be on a schedule dictated by their physician's standard-of-care management protocol. No more than 100mL of blood will be collected per month. Tumor tissue from recurrences will be collected for the duration of subject participation (after the Baseline Visit).
PROBLEM TO BE SOLVED: To provide flowable hemostatic compositions, hemostatic devices using the compositions, and to provide methods of making such compositions and devices.SOLUTION: The invention includes both sterilized and unsterilized hemostatic compositions. The compositions contain a biocompatible liquid. The liquid has particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid. In addition, the compositions contain up to about 20 percent by weight of glycerol and about 1 percent by weight of benzalkonium chloride, each based on the weight of the liquid. All of the liquid are substantially homogenously dispersed throughout the liquid to form a substantially homogenous composition. Furthermore, methods for making such compositions, medical devices that contain such hemostatic compositions disposed therein and methods of making such devices.
Hospital-acquired pneumonia (HAP) development influences the parameters of mechanical ventilation, intensive care unit (ICU) length of stay, hospital length of stay, need of tracheostomy, bronchoscopy, reconnection to MV and mortality. We respect HAP definition: acute inflammation of the respiratory bronchioles, alveolar structures and pulmonary interstitium. Clinically it is defined as the presence of newly developed or progressive infiltrates on chest radiographs plus at least two other signs of respiratory tract infection: temperature \>38 °C, chest pain, purulent sputum, leukocytosis or leukopenia, signs of inflammation on auscultation, cough and/or respiratory insufficiency. HAP is defined as pneumonia that occurs 48 hours or more after admission, which was not incubating at the time of admission. A retrospective, observational study processing data on all consecutive intensive care patients older than 18 years of age between 1 January 2011 and 31 December 2015. The aim was to determine the incidence of potential risk factors and their impact on the development of HAP. The primary outcome was investigation of the relationship between mechanical ventilation parameters and the presence of early- and late-onset HAP. Enrolled in the study were patients staying at the ICU of the Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, between 1 January 2011 and 31 December 2016. The participants were all patients older than 18 years of age consecutively admitted to the ICU.
Fatigued driving is a leading cause of traffic accidents, and accurately predicting driver fatigue can significantly reduce their occurrence. However, modern fatigue detection models based on neural networks often face challenges such as poor interpretability and insufficient input feature dimensions. This article proposes a novel Spatial-Frequency-Temporal Network (SFT-Net) method for detecting driver fatigue using electroencephalogram (EEG) data. Our approach integrates EEG signals' spatial, frequency, and temporal information to improve recognition performance. We transform the differential entropy of five frequency bands of EEG signals into a 4D feature tensor to preserve these three types of information. An attention module is then used to recalibrate the spatial and frequency information of each input 4D feature tensor time slice. The output of this module is fed into a depthwise separable convolution (DSC) module, which extracts spatial and frequency features after attention fusion. Finally, long short-term memory (LSTM) is used to extract the temporal dependence of the sequence, and the final features are output through a linear layer. We validate the effectiveness of our model on the SEED-VIG dataset, and experimental results demonstrate that SFT-Net outperforms other popular models for EEG fatigue detection. Interpretability analysis supports the claim that our model has a certain level of interpretability. Our work addresses the challenge of detecting driver fatigue from EEG data and highlights the importance of integrating spatial, frequency, and temporal information.
Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See DOSAGE AND ADMINISTRATION.)

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.

The physician should also be alert to the possibility of adverse reactions to drug additives diluted and administered from the plastic container. Prescribing information for drug additives to be administered in this manner should be consulted.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
PROBLEM TO BE SOLVED: To prepare a multilayer film preparation having sufficient adhesion even in the case of high wetness at affected part and capable of preventing dropping off, displacement, etc., of the preparation after application by forming double or triple layers and using powder of adhesive polymer in the adhesive layer or drug-containing layer. SOLUTION: Triple layers composed of a drug layer containing a water-soluble polymer as a base component, a nonbonding layer consisting of a water-insoluble layer placed on one side of the drug layer and an adhesion layer containing an adhesive substance placed on the other side of the drug layer are formed. Alternatively, double layers composed of an adhesion layer containing a drug and a nonbonding layer of a water-insoluble layer are formed. The water-insoluble layer preferably contains a ceramic, a higher fatty acid, a water-insoluble cellulose derivative, etc. A hydroxypropylcellulose, a polyvinyl alcohol, etc., is preferably cited as an example of the water-soluble polymer. A carboxyvinyl polymer, a sodium polyacrylate, etc., is cited as an example of the adhesive substance and it is preferably used in the form of powder. A local anesthetic, an analgesic antiphlogistic, an antiinflammatory steroid, a hemostatic agent, an antifungal agent, etc., is preferably used as the drug component. The preparation can be applied especially in the oral cavity.